Published in Blood Weekly, February 8th, 2007
The company also announced that preliminary unaudited revenue for the fourth quarter of 2006 was approximately $44.7 million, a 7% increase over revenue of $41.9 million in the fourth quarter of 2005. Revenue for the fourth quarter of 2006 includes approximately $39.9 million related to product sales and approximately $4.8 million related to the company's research collaboration with Merck & Co., Inc. Revenue for the full year 2006 was approximately $193 million.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.